Climate Change Data

Ocumension Therapeutics 歐康維視生物 (Incorporated in the Cayman Islands with limited liability)

Climate Impact & Sustainability Data (2021, 2022)

Reporting Period: 2021

Environmental Metrics

Social Achievements

  • Inaugurated Suzhou Xiaxiang manufacture site in October 2021 and commenced pilot operation.
  • Acquired rights relating to Emadine® and Betoptic® S in China from Novartis, established a brand-new independent sales team and began to generate its own revenue.

Governance Achievements

  • Established three Board committees: Audit Committee, Remuneration Committee, and Nomination Committee.

Climate Goals & Targets

Environmental Challenges

  • Ongoing COVID-19 pandemic imposed great challenges to the whole industry.
  • Centralized procurement of the Company’s commercialized product in China and the COVID-19 pandemic outbreak in its core sales market.
Mitigation Strategies
  • Effective implementation of foreign currency risk management measures.
  • Established a comprehensive quality management system in line with international standards by taking advantage of the opportunity of the transfer of production of Emadine® and Betoptic® S.

Supply Chain Management

Climate-Related Risks & Opportunities

Reporting Period: 2022

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Not disclosed

Environmental Achievements

  • Not disclosed

Social Achievements

  • Not disclosed

Governance Achievements

  • Established three Board committees: Audit Committee, Remuneration Committee, and Nomination Committee.
  • Adopted a board diversity policy.
  • Implemented a Model Code for Securities Transactions.

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Not disclosed
Short-term Goals:
  • At least two new products to enter the registration stage in 2023.

Environmental Challenges

  • Regional and nationwide recurrence of COVID-19 affected hospital visits, ophthalmic treatment, clinical trials, manufacturing, and product sales.
Mitigation Strategies
  • Closely monitored the pandemic situation and government policies, made appropriate work arrangements for employees, and took preventive measures.

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • The Group selects its suppliers by considering their product quality, industry reputation and compliance with relevant regulations and industry standards.

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: Null

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Not disclosed